PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “CARDIAC VALVES”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 505 records · Page 28Linked to original sources
PubMed1997

Mechanical cardiac valve thrombosis in patients in critical hemodynamic compromise.

BACKGROUND: Valve obstruction is a life threatening complication of mechanical valve prosthesis. METHODS: From 1985 to 1993, 29 consecutive patients were hospitalized in our intensive care unit for mechanical prosthetic valve thrombosis (PVT). There were 12 men and 17 women aged 25-75 years (57 +/- 12). Prosthetic valve location was mitral in 14 patients, aortic in 6, aortic and mitral in 9. PVT occurred from 15 days to 174 months (67 +/- 52 months) after surgery. Delay from first symptoms to hospitalization ranged from 1 to 45 days (11 +/- 11). RESULTS: First clinical symptoms were progressive left heart failure in 17 patients, stroke in 6, and chest pain in 6. Furthermore, acute myocardial infarction was later documented in 3. Left heart failure NYHA III-IV was present in 26 patients (90%) on admission and 10 of those were in cardiogenic shock. Anticoagulation regimen was inadequate in 13 cases (45%). It has been recently stopped in 8 patients and incorrectly conducted in 5. Total hospital mortality was 41.3% (12). It was independent of type and position of the valve prosthesis. Diagnosis of PVT was only made at autopsy in 3 patients who died of recurrent myocardial infarction (2) or cardiogenic shock (1). Five further patients died before any surgery could be attempted (cardiac arrest: 2, cardiogenic shock: 3). Valve replacement could be done in 21 cases, 7 of whom were in cardiogenic shock and 9 had severe pulmonary edema. Four patients died after surgery, the operative mortality was 19%. CONCLUSION: PVT remains a serious complication of mechanical heart valve prostheses. Overall mortality rate is high, related to difficulty to diagnosis, delay to hospitalization and severe clinical condition at admission. In our study, operative risk remained acceptable even when the clinical presentation was severe.

Adult↗
PubMed1989

Assessment of left ventricular functional preservation during isolated cardiac valve operations.

To evaluate intraoperative changes in myocardial performance during valvular operations, ventricular functional measurements were obtained in 16 patients before and after elective cardiac valvular replacement. Six patients had mitral regurgitation, four had mitral stenosis, and six had calcific aortic stenosis; all patients underwent isolated mitral or aortic valve replacement. Cold potassium crystalloid cardioplegia, topical hypothermia, and low-flow systemic hypothermia were employed uniformly. Just before and 10 minutes after cardiopulmonary bypass was discontinued, left ventricular pressure and volume data were recorded at four to five different steady-state levels of filling produced by blood infusion or withdrawal from the aortic cannula (mean end-diastolic pressure range, 10-22 mm Hg; mean end-diastolic volume range, 120-168 ml). Portable first-pass radionuclide ventriculography and simultaneous micromanometry were used for construction of left ventricular pressure-volume loops from which stroke work and end-diastolic volume were calculated. Two-dimensional transesophageal echocardiograms also were recorded, and epicardial pacing maintained heart rate as constant as possible. As compared with prebypass measurements, echocardiographic left ventricular wall volume changed insignificantly after the valvular procedures (178-181 ml/m2, p greater than 0.5). The stroke work-end-diastolic volume relationship before and after operation was highly linear in all studies (mean = 0.97). The slope and x intercept of this relationship did not change significantly after operation, indicating a stable level of left ventricular function (from 12.7 x 10(4) to 10.0 x 10(4) ergs/ml and from 67 to 57 ml, respectively; p greater than 0.3).(ABSTRACT TRUNCATED AT 250 WORDS)

Cardiopulmonary Bypass↗
PubMed1981

Echocardiographic and phonocardiographic assessment of the St. Jude cardiac valve prosthesis.

Forty-three consecutive patients with a St. Jude mitral, aortic, or combined prosthesis were studied by simultaneous phonocardiography and echocardiography. Twenty-eight patients had a mitral prosthesis, 20 an aortic prosthesis, and five had both. No opening click was recorded in any patient; however, a loud aortic or mitral closing click was recorded in all 43 patients. In patients with St. Jude mitral valve prosthesis, an echo-free space separated the two leaflets during diastole; seven of these also had a mid-diastolic closing and late diastolic reopening motion; two of the seven had an associated closing mid-diastolic click. A mid-diastolic rumble was recorded in six of 28 patients with St. Jude mitral valve prosthesis. In patients with a St. Jude aortic valve prosthesis, left atrium leaflet motion was recorded in 17 of 20 patients and was indistinguishable in appearance from echocardiograms obtained with various eccentric monocusp valves. In addition, we report one case of malfunction of a St. Jude mitral valve and one case of a paravalvular leak diagnosed by echophonocardiography. We concluded that the St. Jude cardiac prosthesis has variable normal phonocardiographic-echocardiographic patterns. Knowledge of these variable patterns is important in assessing patients with suspected malfunction of a St. Jude cardiac prosthesis.

Adult↗
PubMed1990

Cardiac valve prostheses at autopsy.

We describe the pathologic findings at autopsy in 96 persons who had undergone prosthetic heart valve implantation. The most common indication for implantation was rheumatic heart disease (58%), followed by infective endocarditis (22%). Cardiac failure led to death in two thirds of the cases, most often from infective endocarditis (18%) and congestive heart failure (13%). Failure of the prosthetic valve caused death in eight cases. There were 13 deaths intraoperatively or in the immediate postoperative period. Patients with mechanical prostheses survived longer than did those with bioprostheses. The most common prosthesis-related complication was thrombosis, found in 23% of mechanical valves and 11% of bioprostheses. Thrombosis led to death in only 4 cases. Thromboembolic phenomena led to nine deaths and were not related to anticoagulant therapy. These findings provide an approach to investigation, description, and diagnosis of prosthetic heart valves at autopsy.

Adolescent↗
PubMed2002

Trauma to cardiac valves.

Cardiorrhaphy is a relatively common procedure performed in a trauma center. However, there is a subgroup of patients with more complicated cardiac injuries such as coronary artery injuries, septal defects, and valvular injuries. Cardiac valvular injuries are often diagnosed subacutely when a new murmur is heard. Transesophageal echocardiography has been increasingly performed to diagnosis these injuries and may be helpful intraoperatively. Cardiac catheterization may be indicated in selected patients. Techniques to address these injuries may involve repair or prosthetic replacement. A high index of suspicion is needed to diagnose these relatively rare injuries.

Cardiac Catheterization↗
PubMed2001

Tissue engineering of cardiac valves on the basis of PGA/PLA Co-polymers.

The limitations of currently used heart valve devices are well known. For prosthetic valves they include infection risk and thrombembolic complications; biologic devices have limited durability. Particularly for pediatric cardiac patients the problem of a lack of growth potential remains a serious issue. The multidisciplinary field of tissue engineering potentially offers an attractive pathway to overcome these disadvantages. The basic concept of tissue engineering is to build a new "tissue" from individual cellular components in vitro using a scaffold to provide an architecture upon which the cells can organize and develop into the desired "tissue" prior to implantation. The scaffold provides the biomechanical profile for the replacement tissue until the cells produce their own extracellular matrix. This newly generated matrix would then ultimately provide the structural integrity and biomechanical profile for the newly developed tissue structure. This work focuses on the concept of using a synthetically produced co-polymer (polyglycolic acid/polylactid acid) as the scaffold for the development of a new generation of heart valves.

Biomechanical Phenomena↗
PubMed1985

Doppler hemodynamic evaluation of prosthetic (Starr-Edwards and Björk-Shiley) and bioprosthetic (Hancock and Carpentier-Edwards) cardiac valves.

One hundred thirty-four patients with prosthetic or bioprosthetic heart valves were investigated with Doppler echocardiography to determine normal values for commonly used prosthetic valves and to test the specificity of abnormal Doppler findings. In 70 patients the aortic valves had been replaced and in 64 the mitral valves had been replaced. Gradients across prostheses in the aortic position were calculated from maximal velocity. Peak calculated aortic transvalvular gradients in normal subjects were 22 +/- 10 mm Hg in 33 Björk-Shiley valves, 23 +/- 10 mm Hg in 27 porcine valves and 29 +/- 13 mm Hg in 6 Starr-Edwards valves. Mild aortic regurgitation was seen in 42% of Björk-Shiley valves, 26% of porcine valves and 2 of 6 Starr-Edwards valves. Mitral valve orifice was calculated by the pressure half-time method. In clinically normal patients with mitral valve prostheses, the effective mitral valve orifice was 2.5 +/- 0.8 cm2 in 35 Björk-Shiley valves, 2.1 +/- 0.7 cm2 in 17 porcine valves, and 2.0 +/- 0.3 cm2 in 10 Starr-Edwards valves. Mitral regurgitation was found in 11% of Björk-Shiley valves, 19% of porcine valves and 30% of Starr-Edwards valves. Repeat studies at 2 weeks to 14 months revealed no difference in 8 aortic and 14 mitral prostheses. Seven aortic and 4 mitral valves functioned abnormally as determined by Doppler, and the abnormal function was confirmed in each at surgery or at cardiac catheterization.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗
PubMed2004

Double-blind, randomized controlled trial on the effect of leukocyte-depleted erythrocyte transfusions in cardiac valve surgery.

BACKGROUND: Leukocytes in allogeneic blood transfusions are believed to be the cause of immunomodulatory events. A few trials on leukocyte removal from transfusions in cardiac surgery have been conducted, and they showed inconclusive results. We found in a previous study a decrease in mortality rates and number of infections in a subgroup of more heavily transfused patients. METHODS AND RESULTS: Patients (n=496) undergoing valve surgery (with or without CABG) were randomly assigned in a double-blind fashion to receive standard buffy coat-depleted (PC) or prestorage, by filtration, leukocyte-depleted erythrocytes (LD). The primary end point was mortality at 90 days, and secondary end points were in-hospital mortality, multiple organ dysfunction syndrome, infections, intensive care unit stay, and hospital stay. The difference in mortality at 90 days was not significant (PC 12.7% versus LD 8.4%; odds ratio [OR], 1.52; 95% confidence interval [CI], 0.84 to 2.73). The in-hospital mortality rate was almost twice as high in the PC group (10.1% versus 5.5% in the LD group; OR, 1.99; 95% CI, 0.99 to 4.00). The incidence of multiple organ dysfunction syndrome in both groups was similar, although more patients with multiple organ dysfunction syndrome died in the PC group. LD was associated with a significantly reduced infection rate (PC 31.6% versus LD 21.6%; OR, 1.64; 95% CI, 1.08 to 2.49). In both groups, intensive care unit stay and hospital stay were similar, and postoperative complications increased with the number of transfused units. CONCLUSIONS: Mortality at 90 days was not significantly different; however, a beneficial effect of LD in valve surgery was found for the secondary end points of in-hospital mortality and infections.

Aged↗
PubMed1999

Cardiac valve papillary fibroelastoma: surgical excision for revealed or potential embolization.

OBJECTIVE: We have reviewed the case histories of 4 patients who underwent operations between September 1994 and November 1997 at Broussais Hospital for cardiac valvular papillary fibroelastoma. METHODS: Diagnosis was strongly suggested by echocardiography. Tumor locations were mitral (1), tricuspid (1), and aortic (2). Indications for operation were previous stroke for the mitral tumor, prophylaxis for the tricuspid tumor, syncopal episodes for the first aortic tumor, and transient ischemic attack and mesenteric ischemia for the second aortic tumor. RESULTS: Surgical excision with a conservative, valve-sparing approach was performed in all cases. For the first aortic tumor, aortic valve reconstruction was achieved with part of a cryopreserved aortic homograft cusp. Intraoperative transesophageal echocardiography showed no evidence of valvular regurgitation after excision in all cases. All patients had uneventful postoperative recoveries. No evidence of regurgitation or recurrence was seen on echocardiography at follow-up. CONCLUSIONS: Despite their histologically benign aspect, cardiac papillary fibroelastomas should be excised because of potential embolic complications. A conservative, valve-sparing approach is recommended, however, because of the absence of recurrence after total excision.

Adult↗
PubMed1987

Thrombolytic therapy for prosthetic cardiac valve thrombosis.

To determine the efficacy and safety of thrombolytic therapy for prosthetic valve thrombosis, a composite series of 41 patients who received either streptokinase or urokinase intravenously for this disorder were analyzed. The series comprised 3 patients treated at Rhode Island Hospital and 38 previously reported on. Short-term success was achieved in 32 patients (78%). Prosthetic valve thrombosis recurred in seven (22%) of the successfully treated patients, four of whom were retreated with thrombolytic therapy. A favorable clinical outcome was observed in each. Fever and venipuncture bleeding were the most frequent side effects. Systemic embolization occurred in 4 (15%) of 26 patients with either aortic or mitral prosthetic valve thrombosis. None of these latter patients experienced a permanent neurologic or circulatory deficit. It is concluded that thrombolytic therapy is of value in the treatment of prosthetic valve thrombosis.

Adult↗
PubMed1989

Plastic surgery for cardiac valves: 15 years' experience.

We suggest that all patients with heart valve diseases should be considered for reconstructive plastic surgery, regardless of the numerous modern mechanical and biological prostheses available in a cardiac surgeon's arsenal. We have 15 years of experience, with 903 plastic surgical procedures with cardiopulmonary bypass for acquired mitral (636), aortic (51), and tricuspid (216) valve diseases. The 15-year survival rate for patients with mitral stenosis was 68% +/- 5%, and the 8-year survival rate for patients with mitral insufficiency was 81% +/- 3%. The 10-year survival rate for patients with mitral and tricuspid valve disease was 59% +/- 3% because of the initially grave condition of such patients. For the correction of acquired aortic valve disease we advocate a new type of operation: a method of stent plasty of the aortic root with two circular sutures placed on the level of the arch and fibrotic ring. In combination with gradual commissurotomy, parietal resection of leaflets and parocommissural plication are performed. This procedure is an effective method for the plastic reconstruction of the aortic valve, and it provides a good hemodynamic effect.

Humans↗